文献速递慢性肾脏病肾血管病与高血压

CKD患者收缩压强化降压目标的争议

Debating targets for systolic blood pressure lowering in CKD.
PubMed 文献 · Nephrol Dial Transplant · 2026-10-12

本文围绕慢性肾脏病(CKD)患者收缩压(SBP)是否应降至<120 mmHg展开辩论。SPRINT试验显示强化降压(<120 mmHg)较标准降压(<140 mmHg)显著降低心血管事件和死亡风险,且CKD亚组获益相似,但KDIGO 2021采纳该目标而ESC、ERA、NICE、ACC/AHA等指南未跟随。文章汇总支持与反对证据并给出共识及临床实施建议。

要点

  • SPRINT试验中强化SBP<120 mmHg较标准<140 mmHg显著降低心血管事件和死亡风险。
  • SPRINT预设亚组分析显示CKD与非CKD患者强化降压获益相似。
  • KDIGO 2021采纳SBP<120 mmHg目标,但ESC、ERA、NICE、ACC/AHA未跟随。

核心结论

  • CKD患者SBP目标是否应<120 mmHg仍存争议,需权衡强化降压的获益与风险。

研究设计与样本

  • 本文为辩论性综述,基于SPRINT试验及其CKD亚组分析等证据展开论述。

主要发现

  • SPRINT显示强化SBP<120 mmHg较标准<140 mmHg显著降低心血管事件和死亡风险。
  • SPRINT预设CKD亚组分析显示强化降压获益与非CKD患者相似。
  • KDIGO 2021采纳SBP<120 mmHg目标,而ESC、ERA、NICE、ACC/AHA未跟随。

关键数值与推荐

  • SPRINT强化目标为SBP<120 mmHg,标准目标为SBP<140 mmHg。

临床怎么用

  • 临床实施SBP<120 mmHg目标需结合患者耐受性及个体化评估。

局限性

  • 本文为辩论性综述,非系统评价或原始研究,证据主要源于SPRINT及其亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For several decades, there was no clinical-trial evidence to demonstrate that intensive blood pressure (BP)-lowering is a therapeutic strategy that prolongs survival and reduces the cardiorenal risk of patients with chronic kidney disease (CKD). In 2015, the landscape changed after the publication of the SPRINT (Systolic Blood Pressure Intervention Trial). Compared with a standard (<140 mmHg) systolic BP (SBP), an impressive cardiovascular and survival benefit was observed with an intensive (<120 mmHg) SBP target in non-diabetic patients with hypertension and high cardiovascular risk provoking premature termination of SPRINT. In 2017, a prespecified subgroup analysis of SPRINT showed that the benefit of intensive BP-lowering was similar in patients with or without CKD. As expected, this landmark trial has substantially influenced the BP target recommendations from the guidelines released thereafter. In 2021, the KDIGO guideline made a breakthrough with the adoption of the intensive SBP target of SPRINT for the management of hypertension in CKD. However, other major medical panels, like ESC, ERA, NICE, ACC and AHA have been reluctant to follow the same approach and the optimal BP goal in CKD continues to be debated. In this article, we provide evidence defending and opposing the position that the SBP target in CKD should be <120 mmHg. We conclude with a consensus and suggestions for the successful implementation of this intensive SBP target in daily clinical practice.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Dounousi E, Georgianos PI, Agarwal R, et al. Debating targets for systolic blood pressure lowering in CKD. Nephrol Dial Transplant. 2026. PMID: 42861937. doi:10.1093/ndt/gfag233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。